%0 Journal Article
%T Ceftolozane/Tazobactam for Resistant Drugs Pseudomonas aeruginosa Respiratory Infections: A Systematic Literature Review of the Real-World Evidence.
%A Giaccari LG
%A Pace MC
%A Passavanti MB
%A Gargano F
%A Aurilio C
%A Sansone P
%J Life (Basel)
%V 11
%N 6
%D May 2021 24
%M 34073847
%F 3.251
%R 10.3390/life11060474
%X <B>BACKGROUND: </B>Ceftolozane/tazobactam (C/T) is a β-lactam/β-lactamase inhibitor combination that mainly targets Gram-negative bacteria. The current international guidelines recommend including C/T treatment in the empirical therapy for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). Pseudomonas aeruginosa (PA) is one of the most challenging Gram-negative bacteria. We conducted a systematic review of all cases reported in the literature to summarize the existing evidence.<BR><B>METHODS: </B>The main electronic databases were screened to identify case reports of patients with drug-resistant PA respiratory infections treated with C/T.<BR><B>RESULTS: </B>A total of 22 publications were included for a total of 84 infective episodes. The clinical success rate was 72.6% across a wide range of comorbidities. The 45.8% of patients treated with C/T presented colonization by PA. C/T was well tolerated. Only six patients presented adverse events, but none had to stop treatment. The most common therapeutic regimens were 1.5 g every 8 h and 3 g every 8 h.<BR><B>CONCLUSIONS: </B>C/T may be a valid therapeutic option to treat multidrug-resistant (MDR), extensively drug-resistant (XDR), pandrug-resistant (PDR), and carbapenem-resistant (CR) PA infections. However, further data are necessary to define the optimal treatment dosage and duration.